Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...
MB-105, a CD5-targeted CAR-T cell therapy, is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess ...
Abpro Holdings, Inc. and Celltrion have announced a strategic partnership for the global development of ABP-102/CT-P72, a bispecific T-cell engager designed to target HER2-positive cancers, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback